NASDAQ:TIL Instil Bio (TIL) Stock Price, News & Analysis $28.23 +4.42 (+18.56%) Closing price 07/3/2025 03:51 PM EasternExtended Trading$28.23 0.00 (0.00%) As of 07/3/2025 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Instil Bio Stock (NASDAQ:TIL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Instil Bio alerts:Sign Up Key Stats Today's Range$23.15▼$30.9050-Day Range$11.72▼$37.5652-Week Range$9.70▼$92.00Volume596,590 shsAverage Volume190,990 shsMarket Capitalization$185.16 millionP/E RatioN/ADividend YieldN/APrice Target$119.00Consensus RatingBuy Company Overview Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas. Read More Instil Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreTIL MarketRank™: Instil Bio scored higher than 52% of companies evaluated by MarketBeat, and ranked 458th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingInstil Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageInstil Bio has only been the subject of 2 research reports in the past 90 days.Read more about Instil Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Instil Bio are expected to grow in the coming year, from ($13.32) to ($11.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Instil Bio is -2.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Instil Bio is -2.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInstil Bio has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Instil Bio's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted24.39% of the float of Instil Bio has been sold short.Short Interest Ratio / Days to CoverInstil Bio has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Instil Bio has recently increased by 33.19%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInstil Bio does not currently pay a dividend.Dividend GrowthInstil Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted24.39% of the float of Instil Bio has been sold short.Short Interest Ratio / Days to CoverInstil Bio has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Instil Bio has recently increased by 33.19%, indicating that investor sentiment is decreasing significantly. News and Social Media1.1 / 5News Sentiment-0.07 News SentimentInstil Bio has a news sentiment score of -0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Instil Bio this week, compared to 1 article on an average week.Search InterestOnly 6 people have searched for TIL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Instil Bio insiders have not sold or bought any company stock.Percentage Held by Insiders47.20% of the stock of Instil Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions60.56% of the stock of Instil Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Instil Bio's insider trading history. Receive TIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Instil Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address TIL Stock News HeadlinesInstil Bio Announces FDA Clearance for IND of AXN-2510, Phase 1 Trial Expected by End of 2025 - NasdaqJuly 3 at 7:40 PM | nasdaq.comInstil Bio stock jumps after FDA clearance of IND applicationJuly 2, 2025 | in.investing.comINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world. | Traders Agency (Ad)Instil Bio Shares Climb After FDA Clears Tumor Treatment ApplicationJuly 2, 2025 | marketwatch.comInstil Bio Shares Surge on FDA Clearance for Investigational Cancer TherapyJuly 2, 2025 | msn.comInstil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid TumorsJuly 2, 2025 | globenewswire.comInstil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody ProgramJune 11, 2025 | globenewswire.comInstil Bio appoints new Chief Medical OfficerJune 4, 2025 | uk.investing.comSee More Headlines TIL Stock Analysis - Frequently Asked Questions How have TIL shares performed this year? Instil Bio's stock was trading at $19.09 at the start of the year. Since then, TIL shares have increased by 47.9% and is now trading at $28.23. How were Instil Bio's earnings last quarter? Instil Bio, Inc. (NASDAQ:TIL) posted its earnings results on Tuesday, May, 13th. The company reported ($4.32) earnings per share for the quarter, missing the consensus estimate of ($2.02) by $2.30. When did Instil Bio's stock split? Shares of Instil Bio reverse split on Friday, December 8th 2023.The 1-20 reverse split was announced on Friday, December 8th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 8th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Instil Bio IPO? Instil Bio (TIL) raised $250 million in an initial public offering (IPO) on Friday, March 19th 2021. The company issued 13,900,000 shares at $17.00-$19.00 per share. Morgan Stanley, Jefferies, Cowen and Truist Securities served as the underwriters for the IPO. How do I buy shares of Instil Bio? Shares of TIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Instil Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Instil Bio investors own include Tesla (TSLA), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Taysha Gene Therapies (TSHA), Viking Therapeutics (VKTX), Golden Minerals (AUMN) and Walt Disney (DIS). Company Calendar Last Earnings5/13/2025Today7/05/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TIL CIK1625584 Webwww.tillcap.com Phone972-499-3350FaxN/AEmployees410Year FoundedN/APrice Target and Rating Average Stock Price Target$119.00 High Stock Price Target$180.00 Low Stock Price Target$52.00 Potential Upside/Downside+321.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($11.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$74.14 million Net MarginsN/A Pretax MarginN/A Return on Equity-45.52% Return on Assets-29.23% Debt Debt-to-Equity Ratio0.58 Current Ratio30.33 Quick Ratio30.33 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$25.96 per share Price / Book1.09Miscellaneous Outstanding Shares6,559,000Free Float3,463,000Market Cap$185.16 million OptionableNo Data Beta2.15 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:TIL) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored140% Yields From Stocks Like Tesla? Here's How (July 4th Special)Imagine getting a 140% dividend from your investments. Even better? It works with big names like Tesla, ...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.The robotics revolution is here. And it's set to impact everything from how we manufacture goods to how we ...Weiss Ratings | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Instil Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Instil Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.